Cogent Biosciences, Inc. (COGT) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.70
↑+43% vs avg
5yr avg: 2.59
30Y Low0.5·High3.8
ROE
↓
-73.7%
-8% vs avg
5yr avg: -68.0%
30Y Low-100%·High-9%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
COGT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cogent Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.9B | $2.4B | $810M | $468M | $679M | $332M | $124M | $22M | $110M | — | — |
| Enterprise Value | $5.9B | $2.3B | $729M | $434M | $559M | $116M | $-112540484 | $-9446164 | $54M | — | — |
| P/E Ratio → | -13.64 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 15.81 | 0.98 | 11.25 | — | — |
| P/B Ratio | 3.70 | 3.77 | 3.16 | 1.82 | 2.66 | 1.55 | 0.53 | 0.69 | 1.82 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
COGT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | -14.30 | -0.42 | 5.53 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
COGT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -73.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | -227.0% | 99.8% | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | — | — | -1044.3% | -143.0% | -369.9% | -312.8% | -300.1% |
| Net Profit Margin | — | — | — | — | — | — | -950.4% | -134.6% | -354.8% | -304.9% | -285.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -73.7% | -73.7% | -99.5% | -74.9% | -59.7% | -32.2% | -56.2% | -65.8% | -78.0% | -63.2% | -29.7% |
| ROA | -52.0% | -52.0% | -79.8% | -62.6% | -52.6% | -29.9% | -49.8% | -44.7% | -51.1% | -40.9% | -21.3% |
| ROIC | -66.4% | -66.4% | -103.7% | -87.0% | -166.5% | — | — | -978.5% | -1174.6% | -353.3% | — |
| ROCE | -58.2% | -58.2% | -100.8% | -75.8% | -60.5% | -33.4% | -60.0% | -66.2% | -72.8% | -49.9% | -24.7% |
COGT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $312M exceeds total debt of $253M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.40 | 0.40 | 0.07 | 0.07 | 0.08 | 0.01 | 0.02 | 0.19 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.31 | -0.13 | -0.47 | -1.01 | -1.01 | -0.99 | -0.92 | -1.00 | -0.79 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -108.87 | -108.87 | — | — | -37.06 | — | — | — | — | — | — |
Net cash position: cash ($312M) exceeds total debt ($253M)
COGT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cogent Biosciences, Inc.'s current ratio of 14.23x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 7.09x to 14.23x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.23 | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 | 18.70 | 3.06 | 3.25 | 3.79 | 7.98 |
| Quick Ratio | 14.23 | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 | 18.70 | 3.06 | 3.25 | 3.78 | 7.98 |
| Cash Ratio | 14.08 | 14.08 | 5.15 | 6.96 | 9.66 | 12.86 | 18.50 | 2.82 | 3.15 | 3.66 | 7.84 |
| Asset Turnover | — | — | — | — | — | — | 0.03 | 0.46 | 0.11 | 0.17 | 0.08 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | 32.45 | 62.55 | 36.24 | 53.30 |
COGT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cogent Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $68M | $104M | $80M | $59M | $39M | $11M | $8M | $6M | $7M | $7M |
Peer Comparison
Compare COGT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 COGTYou | $6B | -13.6 | — | — | — | — | -73.7% | -66.4% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ALGS | $37M | -2.5 | — | — | 57.5% | -4024.9% | -196.9% | -163.0% | — |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 DNLI | $3B | -6.6 | — | — | — | — | -45.7% | -42.8% | — |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
See COGT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COGT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare COGT vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonCOGT — Frequently Asked Questions
Quick answers to the most common questions about buying COGT stock.
What is Cogent Biosciences, Inc.'s P/E ratio?
Cogent Biosciences, Inc.'s current P/E ratio is -13.6x. This places it at the 50th percentile of its historical range.
What is Cogent Biosciences, Inc.'s ROE?
Cogent Biosciences, Inc.'s return on equity (ROE) is -73.7%. The historical average is -58.4%.
Is COGT stock overvalued?
Based on historical data, Cogent Biosciences, Inc. is trading at a P/E of -13.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.